531592 GENPHARMA

Genpharmasec Share Price

 

Stock touched 52W low

 

Start SIP in GENPHARMA

Start SIP

Performance

  • Low
  • ₹1
  • High
  • ₹1
  • 52 Week Low
  • ₹1
  • 52 Week High
  • ₹3
  • Open Price₹1
  • Previous Close₹1
  • Volume2,808,048

Investment Returns

  • Over 1 Month -12.99%
  • Over 3 Month -29.1%
  • Over 6 Month -34.63%
  • Over 1 Year -59.02%

Smart Investing Starts Here Start SIP with Genpharmasec for Steady Growth!

Invest Now

Genpharmasec Fundamentals Fundamentals refer to the financial data that companies report on a quarterly or annual basis.

  • P/E Ratio
  • 135.5
  • PEG Ratio
  • -
  • Market Cap Cr
  • 74
  • P/B Ratio
  • 1.1
  • Average True Range
  • 0.07
  • EPS
  • -
  • Dividend Yield
  • 0
  • MACD Signal
  • -0.06
  • RSI
  • 41.89
  • MFI
  • 57.68

Genpharmasec Financials

Genpharmasec Technicals

EMA & SMA

Current Price
₹1.34
+ 0.05 (3.88%)
pointer
  • Bearish Moving Average 13
  • Bullish Moving Average 3
  • 20 Day
  • ₹1.37
  • 50 Day
  • ₹1.48
  • 100 Day
  • ₹1.65
  • 200 Day
  • ₹1.88

Resistance and Support

1.33 Pivot Speed
  • R3 1.44
  • R2 1.40
  • R1 1.37
  • S1 1.30
  • S2 1.26
  • S3 1.23

Ratings

Master Rating

EPS Strenth

Price Strength

Buyer Demand

Group Rank

Genpharmasec has an operating revenue of Rs. 67.17 Cr. on a trailing 12-month basis. An annual revenue growth of 18% is outstanding, Pre-tax margin of 6% is okay, ROE of 1% is fair but needs improvement. The company has a reasonable debt to equity of 5%, which signals a healthy balance sheet. The stock from a technical standpoint is trading below to its key moving averages. It needs to take out these levels and stay above it to make any meaningful move. From an O'Neil Methodology perspective, the stock has an EPS Rank of 28 which is a POOR score indicating inconsistency in earnings, a RS Rating of 4 which is POOR indicating the underperformance as compared to other stocks, Buyer Demand at E which indicates heavy supply, Group Rank of 160 indicates it belongs to a poor industry group of Medical-Systems/Equip and a Master Score of E is the worst. Overall, the stock has poor technical strength and poor fundamentals, there are superior stocks in the current market environment.

Disclaimer: This stock analysis report is algorithmically generated for informational purposes only and should not be considered as a buy or sell recommendation.

View More

Genpharmasec Corporate Actions - Bonus, Splits, Dividends

Date Purpose Remarks
2025-11-06 Quarterly Results
2025-09-02 Others Inter-alia, to consider 1. Fix the Day, Date, Time and approve Draft notice for the 33rd AGM of the Company. 2. The Directors Report for the year ended 31/03/2025. 3. Other business matters. issue of equity shares of Re. 1/- in the ratio of 1:1 @ premium of Re. 0.75/-.
2025-08-07 Quarterly Results
2025-05-21 Audited Results
2025-03-24 Independent Director Meeting

Genpharmasec F&O

Genpharmasec Shareholding Pattern

29.98%
60.19%
9.83%

Genpharmasec FAQs

Genpharmasec share price is ₹1 As on 03 January, 2026 | 09:46

The Market Cap of Genpharmasec is ₹74.2 Cr As on 03 January, 2026 | 09:46

The P/E ratio of Genpharmasec is 135.5 As on 03 January, 2026 | 09:46

The PB ratio of Genpharmasec is 1.1 As on 03 January, 2026 | 09:46

Open Free Demat Account

Be a part of 5paisa community - The first listed discount broker of India.

+91

By proceeding, you agree to all T&C*

footer_form

Disclaimer: Investment in securities market are subject to market risks, read all the related documents carefully before investing. For detailed disclaimer please Click here.

Q2FY23